Argenx announced positive topline results from a Phase 2 study of FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. The trial met its primary endpoint of change from baseline in the ratio of villus height-to-crypt depth (Vh:Cd) at day 78 versus placebo (p=0.0176). Based on these findings and a consistent safety profile, the company plans to advance FB102 into Phase 3 development. In a separate announcement, argenx will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in Sjögren's disease after an Independent Data Monitoring Committee recommended stopping for futility following an interim analysis. The company operates as a global immunology innovation company developing antibody-based medicines for severe autoimmune diseases.
